Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
ALS Inhibitor/Herbicide
Penoxsulam is a potent acetolactate synthase (ALS) inhibitor that functions as a selective herbicide. It effectively inhibits the enzyme acetohydroxyacid synthase (AHAS) in Candida auris with a Ki value of less than 32 nM. This agent is primarily utilized for postemergence control of annual grasses, sedges, and broadleaf weeds in rice agriculture. Additionally, Penoxsulam serves as a useful tool for investigating Candida auris infections in research contexts. -
CYP51 Inhibitor
CYP51-IN-32 is a selective inhibitor of CYP51, demonstrating a potent antifungal activity with an IC50 of 0.331 μM against Candida albicans. This compound not only inhibits the growth of Candida albicans by disrupting hyphal formation and biofilm development, but it also releases hydrogen sulfide (H2S), contributing to its antifungal effects. CYP51-IN-32 is suitable for investigating Candida albicans infections and can be formulated into PEG-based nanovesicles for enhanced delivery in research applications. -
DHFR Inhibitor
DHFR-IN-25 is a potent inhibitor of dihydrofolate reductase (DHFR), demonstrating broad-spectrum antibacterial activity. This compound exhibits significant efficacy against pathogens such as Candida albicans and Staphylococcus aureus. DHFR-IN-25 is particularly valuable for research applications focusing on local anti-infection strategies and the development of antimicrobial therapies. -
CYP51 Inhibitor
(Rac)-Ketoconazole is an imidazole antifungal agent that acts as a potent inhibitor of cytochrome P450-dependent 14α-sterol demethylase (CYP51). By disrupting ergosterol synthesis, it induces membrane dysfunction, thereby inhibiting the growth and reproduction of various fungi. This compound is primarily utilized in research relating to fungal infections and the mechanisms of antifungal resistance. -
Hsp90 Inhibitor
NSC145366 monohydrochloride is an inhibitor of the Hsp90 chaperone protein, specifically targeting its C-terminal domain. By directly interacting with Hsp90, it effectively disrupts its chaperone activity, leading to a significant reduction in cellular growth. This compound has been shown to strongly inhibit the proliferation of Saccharomyces cerevisiae strains, specifically cog7Δ and cog8Δ, making it a valuable tool for research into protein homeostasis and cellular stress response pathways. -
CYP51 Inhibitor
Pipercroside A is a potent CYP51 inhibitor derived from Piper crocatum Ruiz & Pav. This compound exhibits significant antifungal activity, making it a valuable tool in studies of fungal infections and drug resistance mechanisms. Its role in inhibiting sterol biosynthesis positions Pipercroside A as a candidate for further investigation in antifungal therapeutic development. -
CYP51 Inhibitor
Pipercroside B is a potent inhibitor of CYP51, an essential enzyme in sterol biosynthesis. Isolated from Piper crocatum Ruiz & Pav, this compound exhibits significant antifungal activity, making it valuable for research into antifungal therapeutics. Its role in modulating CYP51 provides insights into fungal metabolism and potential treatment strategies against fungal infections. -
Pyruvate Kinase Inhibitor
PKR-IN-1 is an inhibitor of pyruvate kinase, demonstrating potent antifungal activity with an EC50 of 0.21 μg/mL against Rhizoctonia solani. Its primary mechanism involves the inhibition of glycolytic metabolism, which is crucial for fungal growth and survival. This compound is valuable for research applications focused on the development of antifungal strategies and the study of metabolic pathways in fungi. -
Succinate Dehydrogenase Inhibitor
Siccanin is a potent inhibitor of succinate dehydrogenase (SDH), exhibiting an IC50 of 0.9 μM with selective activity across species. In addition to its role as an SDH inhibitor, Siccanin demonstrates antimicrobial properties against pathogenic fungi. This compound is valuable for research applications focused on metabolic processes and the treatment of fungal infections. -
Succinate Dehydrogenase Inhibitor
SDH-IN-7 is a potent inhibitor of succinate dehydrogenase (SDH), exhibiting an IC50 of 26 nM against porcine SDH. This compound demonstrates significant fungicidal activity, making it a valuable tool for research applications focused on mitochondrial metabolism and fungal pathogenicity. Its inhibitory effect on SDH suggests potential implications in cancer research and metabolic studies. -
HSP90 Inhibitor
HSP90-IN-9 is a highly potent and selective inhibitor of the heat shock protein 90 (HSP90). This compound exhibits pronounced fungicidal activity in a dose-dependent manner and effectively inhibits fungal biofilm formation and morphological alterations when used in conjunction with fluconazole (FLC). Additionally, HSP90-IN-9 enhances FLC sensitivity by down-regulating the expression of key resistance-related genes, including ERG11, CDR1, and CDR2, making it a valuable tool for research applications in antifungal resistance studies. -
Hsp90 Inhibitor
Hsp90-IN-41 is a potent inhibitor of Heat Shock Protein 90 (Hsp90) with an IC50 of 0.044 μM. This compound demonstrates significant antifungal and antitumor activity, exhibiting an IC50 of 0.049 μM in vitro. It is valuable for research applications related to cancer and fungal diseases, particularly in studying the therapeutic potential of Hsp90 modulation. -
Succinate Dehydrogenase Inhibitor
SDH-IN-3 is a potent inhibitor of succinate dehydrogenase (SDH), demonstrating an IC50 of 7.2 μg/mL. This compound exhibits significant antifungal activity against Nigrospora oryzae, with an EC50 of 1.9 μg/mL. SDH-IN-3 is suitable for research applications focused on anti-infection studies and the modulation of metabolic pathways in fungal pathogens. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-3 is a dual inhibitor targeting CYP51 and PD-L1, exhibiting potent antifungal activity with IC50 values of 0.205 μM and 0.039 μM, respectively. This compound induces early apoptosis in fungal cells by reducing levels of intracellular IL-2, NLRP3, and NF-κBp65 proteins. Additionally, CYP51/PD-L1-IN-3 causes mitochondrial damage and reactive oxygen species (ROS) accumulation, ultimately resulting in fungal lysis and cell death. This compound serves as a valuable tool for research in fungal infections and immune modulation. -
Succinate Dehydrogenase Inhibitor
Harzianopyridone is a potent inhibitor of succinate dehydrogenase (SDH), exhibiting an IC50 of 80 nM. Isolated from the fungus Trichoderma harzianum, this compound demonstrates significant antifungal, antibacterial, and herbicidal properties. Harzianopyridone is valuable for research applications exploring metabolic modulation and the study of fungal and bacterial pathways. -
Antifungal Agent/LOX-1 Inhibitor
Sclerotiorin is a reversible uncompetitive inhibitor of soybean lipoxygenase-1 (LOX-1), with an IC50 value of 4.2 μM. This compound exhibits significant antioxidant activity by scavenging free radicals (ED50: 0.12 μM) and inhibiting nonenzymatic lipid peroxidation. Additionally, Sclerotiorin demonstrates antifungal properties and the ability to inhibit platelet aggregation. It can be isolated from the fermented broth of Penicillium frequentans, making it a valuable reagent for research in antifungal mechanisms and oxidative stress studies. -
VEGFR-2/DHFR Inhibitor
VEGFR-2/DHFR-IN-2 is a dual inhibitor of Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) and Dihydrofolate Reductase (DHFR), exhibiting IC50 values of 0.623 μM and 9.085 μM, respectively. This compound demonstrates significant cytotoxic activity against various cancer cell lines, including C26, HepG2, and MCF7, with IC50 values ranging from 3.59 to 8.38 μM. VEGFR-2/DHFR-IN-2 is pertinent for research applications focused on cancer therapeutics and targeted inhibition of tumor angiogenesis. -
DHFR Inhibitor
DHFR-IN-1 is a selective inhibitor of dihydrofolate reductase (DHFR) with an IC50 of 40.71 nM. This compound demonstrates significant antibacterial activity against both gram-positive and gram-negative bacteria, as well as moderate antifungal properties. Additionally, DHFR-IN-1 exhibits a strong synergistic effect when combined with Levofloxacin, characterized by a fractional inhibitory concentration index (FIC) value of 0.249, making it a valuable candidate for further research in antimicrobial applications. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-2 is a quinazoline compound that functions as a dual inhibitor of CYP51 and PD-L1, exhibiting IC50 values of 0.263 μM and 0.017 μM, respectively. It displays notable antifungal activity by triggering early apoptosis in fungal cells, leading to significant reductions in intracellular IL-2, NLRP3, and NF-κBp65 protein levels. Additionally, CYP51/PD-L1-IN-2 induces mitochondrial damage and reactive oxygen species (ROS) accumulation, culminating in fungal lysis and subsequent cell death. This compound is valuable for research exploring antifungal mechanisms and cancer immunotherapy. -
VEGFR-2/DHFR Inhibitor
VEGFR-2/DHFR-IN-1 is a dual inhibitor of VEGFR-2 and dihydrofolate reductase (DHFR), exhibiting IC50 values of 0.384 μM and 7.881 μM, respectively. This compound demonstrates significant antibacterial activity against various strains, including Escherichia coli and MRSA, with MIC values ranging from 8 to 16 μg/mL. Additionally, VEGFR-2/DHFR-IN-1 shows potent cytotoxic effects on cancer cell lines C26, HepG2, and MCF7, with IC50 values between 2.97 and 7.12 μM. This reagent is applicable for research exploring cancer therapeutics and microbial resistance. -
C. albicans Nmt Inhibitor
SC-58272 is a potent and selective inhibitor of N-myristoyltransferase (Nmt) in Candida albicans, exhibiting an IC50 of 56 nM against the strain B311. This compound demonstrates a 250-fold selectivity for the fungal enzyme when compared to the human counterpart. SC-58272 is valuable for research applications involving fungal pathogenesis and the study of myristoylation processes in C. albicans. -
Succinate Dehydrogenase Inhibitor
Succinate dehydrogenase-IN-8 is a potent inhibitor of succinate dehydrogenase (SDH). This indene amino acid derivative exhibits significant antifungal activity in vitro, with effective concentrations against Rhizoctonia solani (EC50=0.1843 mg/L), Botrytis cinerea (EC50=0.4829 mg/L), and Sclerotinia sclerotiorum (EC50=0.1349 mg/L). It is a valuable tool for research applications focused on inhibiting SDH in microbial pathogens. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-1 is a dual inhibitor targeting both CYP51 and PD-L1, exhibiting an IC50 of 0.884 μM for CYP51 and 0.083 μM for PD-L1. This quinazoline compound demonstrates notable antifungal activity by inducing early apoptosis in fungal cells while significantly reducing intracellular levels of IL-2, NLRP3, and NF-κBp65. Additionally, CYP51/PD-L1-IN-1 contributes to mitochondrial damage and reactive oxygen species (ROS) accumulation, ultimately leading to fungal lysis and cell death. This compound is valuable for research focused on antifungal therapies and immune modulation. -
Succinate Dehydrogenase Inhibitor
SDH-IN-8 is a potent inhibitor of succinate dehydrogenase (SDH), demonstrating an IC50 value of 27 nM in porcine SDH assays. This compound exhibits significant fungicidal activity, making it a valuable tool for investigating the role of SDH in fungal metabolism and potential therapeutic applications in fungal infections. Researchers may utilize SDH-IN-8 to explore mechanisms of SDH inhibition and its effects on cellular respiration and metabolic pathways. -
CYP51 Inhibitor
CYP51-IN-19 is a potent inhibitor of cytochrome P450 51 (CYP51), a critical enzyme involved in sterol biosynthesis in fungi. This compound induces the generation of reactive oxygen species (ROS), leading to significant fungicidal activity. It is primarily utilized in antifungal research and the development of therapeutic agents targeting fungal infections. -
Succinate Dehydrogenase Inhibitor
Isofetamid is a potent inhibitor of succinate dehydrogenase, primarily utilized as a fungicide. It demonstrates effective control against a range of fungal pathogens, including gray mold, white mold, and powdery mildew. This compound is valuable for research related to plant fungal diseases, contributing to the understanding of fungal inhibition mechanisms and disease management strategies. -
Phenoloxidase Inhibitor
Phenylthiourea, a phenoloxidase inhibitor, effectively blocks the enzymatic oxidation of DOPA with a Ki value of 0.21 μM. This compound is recognized as a potent inhibitor of tyrosinase, making it valuable in research focused on melanin synthesis and pigmentation processes. Its use can result in observable physiological effects, such as the graying of hair in black rats, highlighting its impact on melanin formation. Phenylthiourea is essential for studies investigating the roles of phenoloxidase and tyrosinase in various biological systems. -
MAO Inhibitor
Norharmane is a reversible monoamine oxidase (MAO) inhibitor, exhibiting IC50 values of 6.5 μM for MAO-A and 4.7 μM for MAO-B. This β-carboline alkaloid demonstrates potential antidepressant effects and may act as an anti-cancer photosensitizer. Additionally, Norharmane has been shown to inhibit polar auxin transport by targeting the PIN2, PIN3, and PIN7 transport proteins, resulting in significant growth suppression of Arabidopsis thaliana seedlings. -
CYP17A1 Inhibitor
YM116 is a potent and orally active competitive inhibitor of CYP17A1, with a reported Ki of 0.38 nM. By specifically inhibiting the C17-20 lyase activity, YM116 effectively reduces the synthesis of adrenal androgens, leading to decreased serum testosterone levels and lower dehydroepiandrosterone sulfate concentrations. This compound is valuable for research applications involving androgen-related disorders and prostate health. -
hCYP3A4 Inhibitor
hCYP3A4-IN-1 is a potent inhibitor of human cytochrome P450 3A4 (hCYP3A4) with notable activity in both human liver microsomes and CHO-3A4 stable cell lines, exhibiting IC50 values of 43.93 nM and 153.00 nM, respectively. This inhibitor effectively blocks CYP3A4-mediated hydroxylation of N-ethyl-1,8-naphthalimide (NEN) in a competitive manner, with a Ki of 30.00 nM. hCYP3A4-IN-1 is valuable for research applications focused on drug metabolism and interactions involving CYP3A4. -
CYP3A4 Inhibitor
Tabimorelin hemifumarate is a potent inhibitor of the cytochrome P450 enzyme CYP3A4. This compound functions as a growth hormone secretagogue, promoting the secretion of growth hormone in the body. Its key biological activities make it valuable for research applications in endocrine signaling and pharmacokinetics, particularly in studies assessing drug metabolism and interactions involving CYP3A4. -
CYP4A Hydroxylase Inhibitor
CAY 10434 is a potent inhibitor of CYP4A hydroxylase, demonstrating significant effects on vascular smooth muscle contractility. This compound enhances the contractile response to angiotensin II, achieving a maximal contractile response (Emax) of 6764 mg. CAY 10434 is valuable for research into cardiovascular physiology and the regulatory mechanisms underlying vascular reactivity. -
CYP11B2 Inhibitor
CYP11B2-IN-3 is a selective inhibitor of CYP11B2, demonstrating an IC50 value of 12.92 nM for CYP11B2 and 2341 nM for CYP11B1. This compound is orally active, making it suitable for in vivo studies. CYP11B2-IN-3 is primarily applicable in research related to hypertension, providing a valuable tool for investigating the role of CYP11B2 in adrenal steroidogenesis and blood pressure regulation. -
CYP1A2/CYP2D6/CYP3A4 Inhibitor
Peucedanol is a non-competitive inhibitor of CYP3A4 with a Ki value of 4.07 μM, while functioning as a competitive inhibitor of CYP1A2 and CYP2D6, with Ki values of 3.39 μM and 6.77 μM, respectively. This compound plays a significant role in pharmacological research by modulating drug metabolism pathways. Its ability to inhibit key cytochrome P450 enzymes makes it a valuable tool for studies examining drug interactions and metabolic regulation. -
CYP3A4 Inhibitor
Licopyranocoumarin is an isoflavonoid known for its inhibitory action on the cytochrome P450 enzyme CYP3A4, exhibiting an IC50 of 32 μM. This compound also demonstrates significant neuroprotective properties, making it a valuable reagent for studies focused on drug metabolism and neurodegenerative disorders. Researchers may utilize Licopyranocoumarin to explore its effects on enzyme activity and potential therapeutic applications in neurological research. -
CYP1B1 Inhibitor
CYP1B1-IN-1 is a selective inhibitor of cytochrome P450 1B1 (CYP1B1) with an IC50 value of 0.49 nM. This compound is valuable for studying the role of CYP1B1 in various biological processes, including the metabolism of xenobiotics and the activation of pro-carcinogens. CYP1B1-IN-1 is suitable for research applications focused on cancer biology and toxicology, providing insights into the pharmacological modulation of CYP1B1 activity. -
CYP450 Inhibitor
11-HETE (11-Hydroxy-5,8,12,14-eicosatetraenoic acid) serves as an activator for cytochrome P450 enzymes. This compound is known to upregulate the mRNA expressions of CYP1B1, CYP1A1, CYP4A11, CYP4F11, and CYP4F2, leading to significant biological effects such as cell hypertrophy in RL-14 cells. Due to its modulatory role in cytochrome P450 activity, 11-HETE holds potential applications in the study of cardiovascular diseases. -
CYP17A1 Lyase Inhibitor
BMS-351 is a potent, orally active nonsteroidal inhibitor of CYP17A1 lyase, demonstrating IC50 values of 19 nM for human CYP17A1 and 4 nM for cynomolgus monkey CYP17A1. This compound is primarily utilized in research focused on castration-resistant prostate cancer, providing insights into hormonal regulation and potential therapeutic interventions in this challenging malignancy. -
CYP1B1 Inhibitor
(E/Z)-DMU2105 is a selective inhibitor of CYP1B1, demonstrating potent inhibition with an IC50 value of 10 nM in yeast-derived microsomes and 63.65 nM in live recombinant yeast and human HEK293 kidney cells. This compound is valuable for research focused on cancer, glaucoma, ischemia, and obesity, offering insights into the role of CYP1B1 in various biological processes. Its specificity and potency make it a suitable tool for elucidating the function of this key enzyme in disease contexts. -
CYP11B2 Inhibitor
CYP11B2-IN-2 is a potent inhibitor of the aldosterone synthase enzyme CYP11B2, exhibiting an IC50 value of 0.3 nM. This compound is labeled with 18F, enabling its application as a positron emission tomography (PET) tracer for the diagnosis of primary aldosteronism. Its high specificity and efficacy make it a valuable tool for research in endocrine disorders and adrenal function. -
CYP2C9/VKOR Inhibitor
10-Hydroxywarfarin is a potent inhibitor of CYP2C9 and vitamin K epoxide reductase complex 1 (VKOR), exhibiting IC50 values of 1.6 µM and 80 ng/mL, respectively. This compound serves as a valuable tool in pharmacological research, particularly in studies related to anticoagulation therapies and vitamin K metabolism. Its role in influencing coagulation pathways makes it relevant for investigations into therapeutic strategies for thrombosis and related disorders. -
CYP1B1 Inhibitor
(E/Z)-DMU2139 is a potent and selective inhibitor of CYP1B1, exhibiting an IC50 value of 4 nM. This compound serves as a valuable tool for investigating the role of CYP1B1 in various biological processes and disease models. Its specificity and efficacy make it suitable for research aimed at understanding the mechanisms underlying CYP1B1-related pathways and the development of targeted therapies. -
HMG-CoA Reductase (HMGCR) Inhibitor
SKF 104976 is a selective inhibitor of HMG-CoA reductase (HMGCR), demonstrating significant inhibitory activity in biochemical assays. It effectively reduces cholesterol synthesis in Hep G2 cells by inhibiting the incorporation of [14C]acetate at concentrations as low as 2 nM, leading to the accumulation of lanosterol and a substantial decrease in HMGR activity by 40-70%. Importantly, SKF 104976 does not influence low-density lipoprotein uptake or degradation, indicating a distinct regulatory mechanism for HMGR and low-density lipoprotein receptors. This compound serves as a valuable tool for studying cholesterol metabolism and the regulation of sterol synthesis pathways in cellular models. -
CYP2C9 Inhibitor
Cloperidone is an inhibitor of cytochrome P450 2C9 (CYP2C9), demonstrating an IC50 of 17.7 μM. This compound has shown cytotoxic effects in HepG2 cells expressing CYP2C9, with a survival rate of 60% at a concentration of 10 μM. Cloperidone is valuable for studies investigating CYP2C9-related metabolic pathways and the effects of its inhibition in cellular models. -
CYP2B4/CYP2E1 Inhibitor
4-Phenyl-1,2,3-thiadiazole is an inhibitor of cytochrome P450 enzymes CYP2B4 and CYP2E1. This compound effectively obstructs the oxidation of 1-phenylethanol to acetophenone, making it valuable for studies related to drug metabolism and enzymatic activity. Its ability to selectively inhibit these enzymes positions it as a significant tool for research in pharmacology and toxicology. -
CYP4Z1 Inhibitor
CYP4Z1-IN-2 is a reversible inhibitor of the enzyme CYP4Z1, displaying a Ki value of 2.2 μM. This compound effectively reduces the production of 14,15-EET in breast cancer cells and demonstrates an IC50 of 5.9 μM in inhibiting the CYP4Z1-mediated Luc-BE O-debenzylation reaction. CYP4Z1-IN-2 serves as a valuable tool for research focused on the role of CYP4Z1 in cancer biology and associated signaling pathways. -
HMG-CoA Inhibitor
tert-Butyl Pitavastatin is a potent inhibitor of HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway. As a metabolite of Pitavastatin, it demonstrates significant biological activity in lowering lipid levels and managing hyperlipidemia. This compound is primarily utilized in pharmacological studies to explore cholesterol regulation and the therapeutic effects of statins in cardiovascular disease research. -
Aha1/Hsp90 Complex Inhibitor
Aha1/Hsp90-IN-1 is a potent inhibitor of the Aha1/Hsp90 complex, demonstrating an IC50 value of 3.32 μM. By disrupting the interactions between Aha1 and Hsp90, this compound effectively inhibits tau aggregation. Research applications include studies of protein folding and aggregation diseases, making it a valuable tool in the exploration of neurodegenerative disorders. -
Serine/Threonine Kinase Inhibitor
ST045945 is a selective inhibitor of serine/threonine kinases, specifically targeting CHK1 and CHK2 pathways that regulate cell cycle checkpoints. This compound effectively induces G2/M phase arrest in tumor cells, leading to DNA damage and inhibition of cell proliferation. ST045945 is utilized in cancer research to explore therapeutic strategies by disrupting critical signaling pathways associated with tumor progression and resistance to chemotherapy. -
5-LO/COX Inhibitor
BW 755C is a dual inhibitor of 5-lipoxygenase (5-LO) and cyclooxygenase (COX) enzymes, exhibiting an IC50 of 5 μM for 5-LO. It also demonstrates inhibitory activity against COX-1 and COX-2, with IC50 values of 0.65 and 1.2 μg/mL, respectively. This compound is valuable for research applications involving inflammation and other related pathways. Its ability to concurrently inhibit key lipid mediators makes BW 755C a useful tool in studies focused on arachidonic acid metabolism and signaling pathways.
